<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Cardiovascular</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/20E66A18-4A43-4DD5-BA98-5320F6EC9269"><gtr:id>20E66A18-4A43-4DD5-BA98-5320F6EC9269</gtr:id><gtr:name>GlaxoSmithKline (GSK)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B8DE35C1-BD77-40C7-A617-698BD33A5AB7"><gtr:id>B8DE35C1-BD77-40C7-A617-698BD33A5AB7</gtr:id><gtr:firstName>Brian</gtr:firstName><gtr:otherNames>John</gtr:otherNames><gtr:surname>Sutton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/5E858FC4-BB7D-4E63-9409-4E82E55F8476"><gtr:id>5E858FC4-BB7D-4E63-9409-4E82E55F8476</gtr:id><gtr:firstName>Maria</gtr:firstName><gtr:otherNames>Rosaria</gtr:otherNames><gtr:surname>Conte</gtr:surname><gtr:orcidId>0000-0001-8558-2051</gtr:orcidId><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/EA8C975A-0C94-4BCE-82DA-19D4FA26832D"><gtr:id>EA8C975A-0C94-4BCE-82DA-19D4FA26832D</gtr:id><gtr:firstName>Michael</gtr:firstName><gtr:otherNames>Stephen</gtr:otherNames><gtr:surname>Marber</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G1001138"><gtr:id>D70E4202-4A66-4C36-A516-3DBCFBF8363D</gtr:id><gtr:title>Preventing TAB1-mediated p38 activation during myocardial infarction</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1001138</gtr:grantReference><gtr:abstractText>During myocardial infarction an enzyme called p38 becomes activated and worsens the injury suffered by the heart. Although p38 can be inhibited with drugs, and this leads to reduced heart injury, these drugs have caused serious side effects in early clinical trials. This is probably because p38 is a very important enzyme throughout the body. The purpose of this grant is to find a way of inhibiting p38 during myocardial infarction by interfering with the way it becomes activated. The reason why this is attractive is that the activation mechanism during myocardial infarction is very unusual in that it requires p38 to bind another protein called TAB1. Thus interfering with this mechanism should not inhibit p38 activation under other circumstances.</gtr:abstractText><gtr:technicalSummary>The activation of 38alpha mitogen-activated protein kinase (p38alpha) during myocardial ischaemia aggravates lethal injury. However, under other circumstances activation of this kinase can protect the heart. During myocardial ischaemia the activation of p38alpha occurs through an unusual mechanism involving a scaffold protein known as TAB1 that causes p38alpha to autophosphorylate its activation loop. 
The purpose of this project is to characterise the molecular basis of the interaction between p38alpha and TAB1 in order to disrupt it. The interface residues on p38alpha and TAB1 will be mapped by NMR chemical shift perturbation and cross-saturation transfer techniques and then confirmed by mutagenesis analysis. The TAB1-induced 3 dimensional rearrangement of p38alpha will also be analysed. This information will be used to design peptides and small molecules to disrupt the TAB1-p38alpha interaction in physiological systems. Such reagents maybe of considerable value since they could prevent the detrimental, but not the beneficial, activation of p38 and thereby perhaps overcome the toxicity seen to date in clinical trials of inhibitors of p38 catalytic activity.</gtr:technicalSummary><gtr:fund><gtr:end>2015-02-28</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>573580</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>GlaxoSmithKline (GSK)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>Discovery Partnership With Academia</gtr:description><gtr:id>811B7BF2-73B6-48EB-8739-28AFAFDABDE0</gtr:id><gtr:impact>None as yet</gtr:impact><gtr:partnerContribution>Provision of novel high through put screen</gtr:partnerContribution><gtr:piContribution>Provision of knowledge, X-ray structures, recombinant proteins and orthogonal screens</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Hosting 4 work experience students each for one week</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>BB632B42-01A2-4902-AE56-94B75109C27A</gtr:id><gtr:impact>Formal feedback good to excellent all domains

Schools requested repeat placements for next year</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2012,2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/8C29005D-E6FA-449C-BEAE-1EE267164036"><gtr:id>8C29005D-E6FA-449C-BEAE-1EE267164036</gtr:id><gtr:title>The activation of p38 alpha, and not p38 beta, mitogen-activated protein kinase is required for ischemic preconditioning.</gtr:title><gtr:parentPublicationTitle>Journal of molecular and cellular cardiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b3f6de537b84b1dfcd7a7ec5228d6038"><gtr:id>b3f6de537b84b1dfcd7a7ec5228d6038</gtr:id><gtr:otherNames>Sicard P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-2828</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/14776618-7F2D-4C94-AE72-42317EF73B73"><gtr:id>14776618-7F2D-4C94-AE72-42317EF73B73</gtr:id><gtr:title>A chemical genetic approach reveals that p38alpha MAPK activation by diphosphorylation aggravates myocardial infarction and is prevented by the direct binding of SB203580.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/8dbe5f527728b7865ff5c8c33acffc71"><gtr:id>8dbe5f527728b7865ff5c8c33acffc71</gtr:id><gtr:otherNames>Kumphune S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5BF70076-4429-43E7-BCA8-3CB5B8280352"><gtr:id>5BF70076-4429-43E7-BCA8-3CB5B8280352</gtr:id><gtr:title>p38 MAPK in cardioprotection - are we there yet?</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/6c7ec72e6fdcaebf866bd9a50224ebac"><gtr:id>6c7ec72e6fdcaebf866bd9a50224ebac</gtr:id><gtr:otherNames>Martin ED</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/68B2D552-C841-4EFE-BDB8-A6956EFACBD4"><gtr:id>68B2D552-C841-4EFE-BDB8-A6956EFACBD4</gtr:id><gtr:title>Effects of p38 mitogen-activated protein kinase inhibition on vascular and systemic inflammation in patients with atherosclerosis.</gtr:title><gtr:parentPublicationTitle>JACC. Cardiovascular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/331f0e6bf5000a1ee15290d747ada88b"><gtr:id>331f0e6bf5000a1ee15290d747ada88b</gtr:id><gtr:otherNames>Elkhawad M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1876-7591</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4B88EC3A-FAE8-4055-BD30-A97587BDB44E"><gtr:id>4B88EC3A-FAE8-4055-BD30-A97587BDB44E</gtr:id><gtr:title>New therapeutic targets in cardiology: p38 alpha mitogen-activated protein kinase for ischemic heart disease.</gtr:title><gtr:parentPublicationTitle>Circulation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/92427b4ab1bba32fda00e3d07383c847"><gtr:id>92427b4ab1bba32fda00e3d07383c847</gtr:id><gtr:otherNames>Denise Martin E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0009-7322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/58AAAAFA-E1AC-458E-A93A-5CA7A2841EF2"><gtr:id>58AAAAFA-E1AC-458E-A93A-5CA7A2841EF2</gtr:id><gtr:title>Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial.</gtr:title><gtr:parentPublicationTitle>Lancet (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/73bf09b5f239ca9adf1ea0c9bc4b892e"><gtr:id>73bf09b5f239ca9adf1ea0c9bc4b892e</gtr:id><gtr:otherNames>Newby LK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0140-6736</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0403352F-751E-4D70-B7BF-BC607798061E"><gtr:id>0403352F-751E-4D70-B7BF-BC607798061E</gtr:id><gtr:title>Mechanism and consequence of the autoactivation of p38a mitogen-activated protein kinase promoted by TAB1.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/97e4bde5456def0b4abfa1a8d83a5996"><gtr:id>97e4bde5456def0b4abfa1a8d83a5996</gtr:id><gtr:otherNames>De Nicola GF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4A70E1C5-863E-4F91-9D78-81C60EC685B9"><gtr:id>4A70E1C5-863E-4F91-9D78-81C60EC685B9</gtr:id><gtr:title>Developing small molecules to inhibit kinases unkind to the heart: p38 MAPK as a case in point.</gtr:title><gtr:parentPublicationTitle>Drug discovery today. Disease mechanisms</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/99cf258918bd7b3866fa8aeba91e35b3"><gtr:id>99cf258918bd7b3866fa8aeba91e35b3</gtr:id><gtr:otherNames>Marber MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1740-6765</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1001138</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>